• OraSure Reports 1Q22 Record Revenue of $67.7 Million; 16% Year-Over-Year With 21% Growth in Non-COVID Revenue

    ソース: Nasdaq GlobeNewswire / 10 5 2022 15:05:01   America/Chicago

    InteliSwab® revenue of $22.1 million in Q1, up 50% sequentially with significant scaling in production

    Non-COVID molecular kits increase 42% year-over-year demonstrating continued strong growth

    Management to Host Analyst/Investor Call and Webcast Today at 5:00 p.m. ET

    BETHLEHEM, Pa., May 10, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced its financial results for the three months ended March 31, 2022.

    “We made significant progress in the quarter scaling InteliSwab® production and improving the efficiency of our manufacturing process as we look to drive profitable growth,” said OraSure Interim President and CEO Nancy J. Gagliano, M.D., MBA. “Excluding COVID-19 products, both our Diagnostics and Molecular Solutions businesses grew at a double-digit rate year-over-year.”

    She continued, “We once again saw exceptionally strong demand for our molecular kits business, with our non-COVID-19 core collection kit business growing 36% versus the same quarter a year ago. We also continue to launch innovative offerings such as our first-of-its-kind U.S. Food and Drug Administration (FDA) de novo authorized microbiome gut collection kit and our new metatranscriptome services offering, with new offerings to be launched this quarter. In addition, we continue to expand our market coverage with our base of active purchasing Molecular Solutions customers growing 6% in the quarter, positioning us for continued long-term growth.”

    Financial Highlights

    • Net revenues for the first quarter of 2022 were $67.7 million, a 16% increase from the first quarter of 2021 and a new record for the Company. Excluding COVID-19 product revenues, revenues for the quarter increased 21% year-over-year.
    • Total revenues from the Company’s Diagnostic business unit were $38.3 million during the first quarter of 2022 and grew 163% relative to the same period last year. Revenue growth was driven primarily by InteliSwab®. Excluding InteliSwab® sales, total Diagnostic business unit revenue grew 11% year-over-year.
    • Total product and service revenues for the Company’s Molecular Solutions business unit were $29.4 million during the first quarter of 2022, a decline of 33% from the first quarter of 2021. The decline was driven entirely by lower sales of the Company’s COVID-19 molecular collection kits given the expected transition to point of care solutions, as well as customers working through high inventory levels. Excluding these COVID-19 revenues, the molecular solutions business grew 28% year-over-year.
    • Gross margin in the first quarter was 36% and was negatively impacted by one-time InteliSwab® manufacturing costs including high scrap rates during the quarter and under-absorption as the Company worked to scale InteliSwab® production. Additionally, average selling prices for InteliSwab® declined on a sequential basis as the mix of the first quarter revenue was primarily related to the Company’s government procurement contract compared to fourth quarter 2021 revenue which consisted of predominantly commercial sales. Furthermore, product mix drove declining margins with more revenue coming from the Company’s Diagnostic business unit, as well as lower revenues from higher margin COVD-19 collection kits. In addition, gross margin was negatively impacted by the expiration of subsidies for the international sale of our HIV Self-Test under the charitable support agreement with the Gates Foundation ,which expired in June 2021. The Company currently has a number of programs in place which are intended to improve gross margins including efficiency programs associated with production, changes in logistical processes, product packaging redesign, and supply chain consolidation.
    • Operating loss in the first quarter was ($16.0) million compared to operating income of $10.4 million in the first quarter of last year. OraSure’s operating loss in the quarter was driven by an increase in investments to support the InteliSwab® scale-up, one-time production inefficiencies, continued development, and approximately $4.9 million in one-time expenses tied to the company’s strategic alternative process and CEO transition.
    • Cash flow used in operations in the quarter was ($35.8) million which was impacted by working capital changes due to increases in accounts receivable and inventory levels associated with the InteliSwab® scale up. Cash and investments totaled $112.2 million at March 31, 2022. As of March 31, 2022, the Company also had approximately $16.9 million in funds committed to the capacity expansion build out associated with the Department of Defense contract which will be reimbursed in future periods.

    Recent Business Highlights

    InteliSwab® COVID-19 Testing

    • InteliSwab® revenue in the quarter grew to $22.1 million representing over 50% sequential growth relative to the fourth quarter.
    • Production volumes of InteliSwab® scaled dramatically during the first quarter. In early April, the company demonstrated the ability to produce tests at volume equivalent to the Company’s installed capacity representing over a four-fold increase from production levels in early January. During the quarter, the company resolved major production issues and is now in full production phase.
    • The Company has been highly focused on improving production efficiencies as well. Finished goods scrap rates for InteliSwab declined to less than 1% by late March from over 30% in early January.
    • OraSure announced that the InteliSwab® COVID-19 rapid tests detect the Omicron variant with similar limits of detection to the original SARS-CoV-2 strain and other previous variants of concern, including Delta, Alpha, Beta and Gamma. 

    Diagnostics Business Results (excluding InteliSwab®)

    • Excluding InteliSwab® revenue, the Diagnostics legacy revenue was $16.2M and grew 11% compared to the prior year quarter.
    • International Diagnostics revenue was $5.6M in Q1, a20% increase compared to the prior year period. Excluding the impact of the Bill and Melinda Gates Foundation subsidy expiry in June 2021, the business grew 34% year-over-year.
    • U.S. Diagnostics revenue, excluding InteliSwab®, was $10.5M and grew 7% year-over-year despite lapping the Q1 2021 Center for Disease Control’s, “Let’s Stop HIV Together,” home testing program which was not repeated this quarter.
    • The Company launched the OraQuick® HIV Self-Test, an oral swab in-home test for HIV-1 and HIV-2, into Europe. The test will be available in six European countries: United Kingdom, Germany, France, Italy, Spain and Portugal.

    Molecular Solutions

    • Genomics collection kit revenue of $15.1 million for the first quarter of 2022 grew 40% year-over-year.
    • Sales of OraSure’s sample collection devices for molecular/PCR COVID-19 testing decreased 68% year-over-year to $8.9 million in the first quarter of 2022 compared to $28.0 million in the prior year period. The decline in revenue is attributable to lower testing volumes with core customers as the market transitions to point-of-care solutions such as rapid antigen tests and customers work through current inventory levels of collection kits.
    • Total microbiome revenue, including kits and services, was $3.7 million in the quarter and declined 12% relative to the first quarter of last year. During the quarter, services revenue was negatively impacted by the delayed timing of customer clinical trials. Microbiome collection kits grew 14% in Q1 compared to the prior year.
    • Received U.S. Food and Drug Administration (FDA) de novo authorization for the OMNIgene®·GUT Dx (OMD-200) microbiome collection device and commercially launched the product. OMNIgene®·GUT Dx is the first FDA approved collection kit specifically targeted to the collection of stool-based microbiome samples.
    • Launched a new service to provide metatranscriptomic sequencing and analysis of gut microbiome samples through the Company’s Diversigen subsidiary. As part of the launch, the company created a comprehensive, curated database with more than 190,000 genomes, representing 31,000 species of microbes, to allow profiling of microbial gene expression, including functional modules and pathways. Metatranscriptomic sequencing provides powerful insights not possible with other sequencing technologies.

    Strategic Alternatives Review and CEO Search

    On January 5, 2022, the Company announced it is exploring strategic alternatives. The review is ongoing, and no decisions have been made.

    Consistent with the first quarter, OraSure will not be providing guidance for the second quarter given the ongoing strategic alternative process.

    Additionally, the company has hired an external search firm and is in the process of looking for a permanent chief executive officer. Dr. Nancy J. Gagliano has been appointed as interim President and CEO by the Board of Directors and is not a candidate for the full-time position.

    Financial Data (Unaudited)

      Three Months Ended
      March 31,
       2022   2021 
    Results of Operations    
    Net revenues $67,707  $58,582 
    Cost of products and services sold  43,435   20,256 
    Gross profit  24,272   38,326 
    Operating expenses:    
    Research and development  8,413   8,992 
    Sales and marketing  12,717   9,530 
    General and administrative  19,156   10,188 
    Change in fair value of acquisition-related contingent consideration  (36)  (806)
    Total operating expenses  40,250   27,904 
    Operating income (loss)  (15,978)  10,422 
    Other expense  (53)  (119)
    Income (loss) before income taxes  (16,031)  10,303 
    Income tax expense  3,936   6,529 
    Net income (loss) $(19,967) $3,774 
    Earnings (loss) per share:    
    Basic $(0.28) $0.05 
    Diluted $(0.28) $0.05 
    Weighted average shares:    
    Basic  72,194   71,878 
    Diluted  72,194   72,766 
         


     Three Months Ended 
     March 31, 
      2022  2021 %Change 
    DIAGNOSTICS      
    Infectious Disease Testing Revenues      
    Domestic HIV$3,765 $5,293 (29)%
    International HIV 4,401  3,486 26  
    Net HIV revenues 8,166  8,779 (7) 
    Domestic HCV 2,036  1,182 72  
    International HCV 1,221  1,184 3  
    Net HCV revenues 3,257  2,366 38  
    Net OraQuick® revenues 11,423  11,145 2  
    COVID-19 22,136  - NM 
    Other infectious disease revenues 277  226 23  
    Total Infectious Disease 33,836  11,371 198  
    Risk Assessment 2,560  1,962 30  
    Other non-product revenues 1,914  1,213 58  
    TOTAL DIAGNOSTIC NET REVENUE 38,310  14,546 163  
           
    MOLECULAR SOLUTIONS      
    Genomics$15,093 $10,818 40  
    Microbiome 1,990  1,751 14  
    COVID-19 8,896  27,972 (68) 
    Laboratory services 1,733  2,497 (31) 
    Other product and services revenues 1,128  208 442  
    Net product and service revenues 28,840  43,246 (33) 
    Other non-product and service revenues 557  790 (29) 
    TOTAL MOLECULAR SOLUTIONS NET REVENUE 29,397  44,036 (33) 
           
    TOTAL NET REVENUES$67,707 $58,582 16 %
           


    Condensed Consolidated Balance Sheets (Unaudited)  
      March 31, 2022 December 31, 2021
    Assets    
    Cash and cash equivalents $70,721 $116,762
    Short-term investments  41,503  36,279
    Accounts receivable, net  59,671  45,323
    Inventories  61,536  53,138
    Other current assets  34,933  36,929
    Property, plant and equipment, net  97,572  88,164
    Intangible assets, net  13,692  14,343
    Goodwill  40,389  40,279
    Long-term investments  -  17,009
    Other noncurrent assets  15,515  12,764
    Total assets $435,532 $460,990
         
    Liabilities and Stockholders’ Equity    
    Accounts payable $27,057 $28,024
    Deferred revenue  2,906  2,936
    Other current liabilities  25,624  37,104
    Other non-current liabilities  15,059  12,393
    Stockholders’ equity  364,886  380,533
    Total liabilities and stockholders’ equity $435,532 $460,990
         


    Additional Financial Data (Unaudited)
    		 Three months ended
      March 31,
       2022  2021
    Capital expenditures $22,074 $11,061
    Depreciation and amortization $3,682 $2,489
    Stock-based compensation $3,524 $1,464
    Cash used in operating activities $35,821 $4,393
         

    Conference Call

    The Company will host a conference call and audio webcast for analysts and investors to discuss the Company’s first quarter 2022 results and certain business developments, beginning today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). On the call will be Dr. Nancy J. Gagliano, President and Chief Executive Officer, Lisa Nibauer, President Diagnostics, Kathleen Weber, President Molecular Solutions, and Scott Gleason, Interim Chief Financial Officer. The call will include prepared remarks by management and a question and answer session.

    In order to listen to the conference call, please dial (877) 344-8082 (Domestic) or (213) 992-4618 (International) and reference Conference ID #4956626 with pin number 3180 or go to OraSure Technologies’ web site, www.orasure.com, and click on the Investor Relations page. Please click on the webcast link and follow the prompts for registration and access 10 minutes prior to the call. A replay of the call will be archived on OraSure Technologies’ web site shortly after the call has ended and will be available for 14 days. A replay of the call can also be accessed until midnight, May 24, 2022, by dialing 800-645-7964 and entering playback ID: 4132#.
    It is recommended to dial-in at most 15 to 20 minutes prior to the call start to reduce waiting times. If a participant will be listen-only, they are encouraged to listen via the webcast on OraSure’s Investor Relations page.

    About InteliSwab®
    OraSure has received Emergency Use Authorizations (EUA) from the FDA for its InteliSwab® COVID-19 rapid tests. The FDA has authorized the InteliSwab® COVID-19 Rapid Test for Over-the-Counter (OTC) use without a prescription. The FDA has also authorized the InteliSwab® COVID-19 Rapid Test Pro for professional use in point of care (POC) CLIA-waived settings, and the InteliSwab® COVID-19 Rapid Test Rx for Prescription Home Use. These remarkably simple COVID-19 lateral flow tests use samples self-collected from the lower nostrils. InteliSwab®’s unique design incorporates a built-in swab fully integrated into the test stick. After users swab their lower nostrils, the test stick is swirled in a pre-measured buffer solution, and the result appears right on the test stick within 30 minutes, with no instruments, batteries, smartphone or laboratory analysis needed to see the result. With less than one minute of “hands-on time,” it is as simple as “Swab, Swirl, and See.”

    This product has not been FDA cleared or approved, but it has been authorized by the FDA under an EUA. The emergency use of this product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. This product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb- 3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

    Multiple government agencies, including the U.S. Department of Defense (DoD) and Department of Health and Human Services (HHS) are working to address COVID-19 testing needs. Development of the InteliSwab® COVID-19 Rapid Test has been funded in whole or in part with federal funds from the HHS; the Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, Division of Research, Innovation and Ventures under contract numbers 75A50120C00061 and 75A50121C00078, utilizing Health Care Enhancement Act (HCEA) funding. The DoD's Defense Assisted Acquisition (DA2) Cell led the manufacturing expansion effort for the InteliSwab® COVID-19 rapid test in coordination with the Department of the Air Force’s Acquisition COVID-19 Task Force (DAF ACT). The manufacturing effort was funded through the American Rescue Plan Act (ARPA) to enable and support domestic industrial base expansion for critical medical resources.

    About OraSure Technologies
    OraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information. OraSure, together with its wholly-owned subsidiaries, DNA Genotek, Diversigen, and Novosanis, provides its customers with end-to-end solutions that encompass tools, services and diagnostics. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharma, commercial entities and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com.

    Important Information
    This press release contains certain forward-looking statements, including with respect to products, product development activities, regulatory submissions and authorizations, revenue growth, increasing margins and other matters. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: risk that the Company's exploration of strategic alternatives may not result in any definitive transaction or enhance stockholder value and may create a distraction or uncertainty that may adversely affect operating results, business or investor perceptions; the diversion of management’s attention from the Company's ongoing business and regular business responsibilities due to the Company's exploration of strategic alternatives; ability to resolve the Company's ongoing manufacturing challenges and satisfy customer demand; ability to market and sell products, whether through our internal, direct sales force or third parties; impact of significant customer concentration in the genomics business; failure of distributors or other customers to meet purchase forecasts, historic purchase levels or minimum purchase requirements for our products; ability to manufacture products in accordance with applicable specifications, performance standards and quality requirements; ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indications or applications for existing products; ability to comply with applicable regulatory requirements; ability to effectively resolve warning letters, audit observations and other findings or comments from the U.S. Food and Drug Administration (“FDA”) or other regulators; the impact of the novel coronavirus (“COVID-19”) pandemic on the Company's business, supply chain, labor force, and ability to successfully develop new products, validate the expanded use of existing collector products, receive necessary regulatory approvals and authorizations and commercialize such products for COVID-19 testing; changes in relationships, including disputes or disagreements, with strategic partners or other parties and reliance on strategic partners for the performance of critical activities under collaborative arrangements; ability to meet increased demand for the Company’s products; impact of replacing distributors; inventory levels at distributors and other customers; ability of the Company to achieve its financial and strategic objectives and continue to increase its revenues, including the ability to expand international sales; impact of competitors, competing products and technology changes; reduction or deferral of public funding available to customers; competition from new or better technology or lower cost products; ability to develop, commercialize and market new products; market acceptance of oral fluid or urine testing, collection or other products; market acceptance and uptake of microbiome informatics, microbial genetics technology and related analytics services; changes in market acceptance of products based on product performance or other factors, including changes in testing guidelines, algorithms or other recommendations by the Centers for Disease Control and Prevention (“CDC”) or other agencies; ability to fund research and development and other products and operations; ability to obtain and maintain new or existing product distribution channels; reliance on sole supply sources for critical products and components; availability of related products produced by third parties or products required for use of our products; impact of contracting with the U.S. government; impact of negative economic conditions; ability to maintain sustained profitability; ability to utilize net operating loss carry forwards or other deferred tax assets; volatility of the Company’s stock price; uncertainty relating to patent protection and potential patent infringement claims; uncertainty and costs of litigation relating to patents and other intellectual property; availability of licenses to patents or other technology; ability to enter into international manufacturing agreements; obstacles to international marketing and manufacturing of products; ability to sell products internationally, including the impact of changes in international funding sources and testing algorithms; adverse movements in foreign currency exchange rates; loss or impairment of sources of capital; ability to attract and retain qualified personnel; exposure to product liability and other types of litigation; changes in international, federal or state laws and regulations; customer consolidations and inventory practices; equipment failures and ability to obtain needed raw materials and components; the impact of terrorist attacks, civil unrest, hostilities and war ; and general political, business and economic conditions. These and other factors that could affect our results are discussed more fully in our SEC filings, including our registration statements, Annual Report on Form 10-K for the year ended December 31, 2021, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. Readers are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are made as of the date of this press release and OraSure Technologies undertakes no duty to update these statements.

    Investor Contact:Media Contact:
    Scott GleasonAmy Koch
    Interim CFO SVP Investor Relations & Corp. CommunicationsSr. Mgr. Corporate Communications
    484-425-0588484-523-1815
    sgleason@orasure.commedia@orasure.com 
      

    Primary Logo

シェアする